In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
TrumpRx: Enabling direct-to-patient care?
As of December 11, 2025, a variety of manufacturers have reached agreements or stated their intent to offer discounted prices for some of their medications...